BioVie (BIVI)

• Market cap: $35.7M
• 1 day: -4.29%
• 5 days: -21.18%
• 1 month: -20.87%
• 3 months: 76.32%
• 6 months: -53.90%
• Year to date: -7.80%
• 1 year: -84.05%
• 5 years: -97.99%
• 10 years: -97.99%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 14

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5.23% less ownership

Funds ownership: 7.35% [Q2] → 2.12% (-5.23%) [Q3]

46% less funds holding

Funds holding: 50 [Q2] → 27 (-23) [Q3]

76% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 29

89% less capital invested

Capital invested by funds: $1.8M [Q2] → $195K (-$1.6M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 20